Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424589 | 0.77 | KMT2A (0.39) | SMN1; SMN2 | |
| SCHEMBL4079827 | 0.69 | KEAP1 (0.32) | KEAP1SMN1; SMN2SIGMAR1CYP2D6 | |
| SCHEMBL6223267 | 0.69 | KEAP1 (0.54) | KEAP1SMN1; SMN2SIGMAR1CYP2D6HSD17B10 | |
| SCHEMBL19624309 | 0.68 | KEAP1 (0.34) | KEAP1SMN1; SMN2 | |
| SCHEMBL19439256 | 0.68 | PIK3CD (0.55) | KEAP1SMN1; SMN2SIGMAR1CYP2D6HSD17B10 | |
| SCHEMBL1959159 | 0.67 | SMN1; SMN2 (0.38) | KEAP1SMN1; SMN2 | |
| SCHEMBL7557613 | 0.66 | — | — | |
| SCHEMBL101501 | 0.65 | KEAP1 (0.67) | KEAP1SMN1; SMN2SIGMAR1CYP2D6HSD17B10 | |
| SCHEMBL1616800 | 0.65 | — | — | |
| SCHEMBL11232864 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540338-B2 | Substituted cinnamic acid amides for treating pain | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2940003-A1 | CINNAMIC ACID AMIDE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | OPRL1, TRPV1, TRPA1 | KEAP1 537/4885SMN1; SMN2 929/4885SIGMAR1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.